In This Article:
-
Total Revenue (Q4 2024): $59.9 million, up 33% from $45.1 million in Q4 2023.
-
Total Revenue (Full Year 2024): $235.1 million, up 34% from $175.5 million in 2023.
-
Net Product Sales of LUPKYNIS (Q4 2024): $57.6 million, up 36% from $42.3 million in Q4 2023.
-
Net Product Sales of LUPKYNIS (Full Year 2024): $216.2 million, up 36% from $158.5 million in 2023.
-
Cash Flow from Operations (Q4 2024): $30.1 million compared to $14.3 million in Q4 2023.
-
Cash Flow from Operations (Full Year 2024): $44.4 million compared to cash flow used in operations of $33.5 million in 2023.
-
Cash Equivalents, Restricted Cash, and Investments (End of 2024): $358.5 million.
-
Gross Margin (Q4 2024): 91% compared to 88% in Q4 2023.
-
Gross Margin (Full Year 2024): 88% compared to 92% in 2023.
-
Total Operating Expenses (Q4 2024): $61.5 million compared to $74.8 million in Q4 2023.
-
Total Operating Expenses (Full Year 2024): $239.8 million compared to $267.2 million in 2023.
-
Net Income (Q4 2024): $1.4 million or $0.01 per share compared to a net loss of $26.9 million or $0.19 per share in Q4 2023.
-
Net Income (Full Year 2024): $5.8 million or $0.04 per share compared to a net loss of $78 million or $0.54 per share in 2023.
Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a significant growth in total revenue, with a 33% increase in the fourth quarter of 2024 compared to the same period in 2023.
-
Net product sales of LUPKYNIS increased by 36% in both the fourth quarter and full year of 2024, driven by further market penetration.
-
The company generated positive cash flow from operations, improving from a cash flow deficit in 2023 to a positive cash flow of $44.4 million in 2024.
-
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a strong cash position with cash equivalents, restricted cash, and investments totaling $358.5 million as of December 31, 2024.
-
The company is advancing its pipeline with the development of AUR200, a potentially best-in-class dual BAFF and APRIL inhibitor, with initial results expected in the second quarter of 2025.
Negative Points
-
The cost of revenue increased significantly for the full year 2024, primarily due to the amortization of the finance rate of use lease asset.
-
Gross margin decreased from 92% in 2023 to 88% in 2024, indicating a slight decline in profitability.
-
Total operating expenses, although reduced, still amounted to $239.8 million for the year, reflecting ongoing high costs.
-
The company ceased development of its AUR300 program, which may impact future growth opportunities.
-
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) faces potential competition and patent challenges, with generic filings expected, which could impact future market exclusivity for LUPKYNIS.